Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users

Abstract

This cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in Rio Grande do Norte, Brazil. Economic, socio-demographic, anthropometric, biochemical, and hormonal variables were compared. The EuroQoL Five-Dimension Scale (EQ-5D) was used to evaluate quality of life, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson-Angus Scale. Data were analysed using the χ(2) test and Student's t test, with a significance level of 5 %.The household incomes of approximately 80 % of patients were <2.0 minimum wages ($678). Anthropometric variables (waist circumference, hip circumference, weight, waist-to-hip ratio) and systolic and diastolic blood pressure were noted among male olanzapine users (all p < 0.05). EQ-5D scores showed that olanzapine use significantly impacted self-help ability (p < 0.001). Risperidone users had a mean quality-adjusted life year value of 1. Mean total Simpson-Angus Scale scores was 0.38 for olanzapine users and 0.11 for risperidone users (p < 0.02). Significant differences in UKU were observed for the following items: asthenia/lassitude/fatigue (higher among olanzapine users, p = 0.02), dystonia (higher among olanzapine users, p = 0.01), tremors (higher among olanzapine users, p = 0.03), gynecomastia (higher among risperidone users, p < 0.02), and ejaculatory dysfunction (higher among risperidone users, p < 0.02). Olanzapine users had impaired quality of life, which can be explained in part by adverse motor, biochemical, and hormonal effects characteristic of metabolic syndrome.

Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics

“…The scale is scored by averaging the individual items. We considered patients with extrapyramidal manifestations those patients who achieved values greater than 0.3 in the SAS [11][12][13]. Prestudy sessions with the research team members in charge of applying the SAS were organized and a pilot study in ten patients was conducted under supervision of the authors.…”

Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?

“…Èññëåäîâàíèÿ âîïðîñà ëåêàðñòâåííî-èíäóöèðîâàííûõ ýêñòðàïèðàìèäíûõ ðàññòðîéñòâ, â òîì ÷èñëå àêàòèçèè, â ðàìêàõ êîíñòèòóöèîíàëüíîãî íàïðàâëåíèÿ âñòðå÷àþòñÿ ëèøü â åäèíè÷íûõ ñëó÷àÿõ. Òàê, ãðóïïîé àâòîðîâ [15] áûëî îïèñàíî âëèÿíèå îòäåëüíûõ àíòðîïîìåòðè÷åñêèõ ïîêàçàòåëåé (äëèíà òåëà, îêðóaeíîñòü òàëèè, áåäåð, îòíîøåíèå îêðóaeíîñòè òàëèè ê îêðóaeíîñòè áåäåð) íà âîçíèêíîâåíèå ïîáî÷íûõ ëåêàðñòâåííî-èíäóöèðîâàííûõ ÿâëåíèé, êîòîðûå áûëè îòìå÷åíû ó ìóae÷èí, ïðèíèìàþùèõ îëàíçàïèí. Ðÿä ïîäîáíûõ èññëåäîâàíèé òàêaeå íå îòðàaeàåò ïîëíîãî è öåëîñòíîãî ïîäõîäà ê äàííîìó âîïðîñó [16][17][18].…”